Published in Clin Pharmacol Ther on May 01, 2012
Polypharmacy in the elderly from the clinical toxicologist perspective. Z Gerontol Geriatr (2012) 0.82
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med (1999) 82.86
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med (1999) 7.74
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet (1999) 7.39
Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J (2007) 7.34
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.12
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature (2004) 5.95
Systematic overview of warfarin and its drug and food interactions. Arch Intern Med (2005) 5.86
Diagnosing model diagnostics. Clin Pharmacol Ther (2007) 4.17
The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med (1996) 3.79
Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed (2008) 3.44
Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med (2003) 3.18
Hemorrhagic complications of anticoagulant treatment. Chest (2001) 2.76
Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res (2006) 2.55
Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres. BMJ (2000) 2.49
Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther (2002) 2.23
Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood (2005) 1.95
Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinet (1987) 1.84
Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med (2001) 1.69
Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet (1985) 1.60
Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J Thromb Thrombolysis (2007) 1.47
Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. Thromb Haemost (2009) 1.34
The morbidity related to atrial fibrillation at a tertiary centre in one year: 9.0% of all strokes are potentially preventable. J Clin Neurosci (2002) 1.26
Antithrombotic therapy for atrial fibrillation. BMJ (2002) 1.22
Vitamin K epoxide reductase genetic polymorphism is associated with venous thromboembolism: results from the EDITH Study. J Thromb Haemost (2007) 1.16
Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment). Haematologica (2001) 1.06
Safety of treatment with oral anticoagulants in the elderly. A systematic review. Drugs Aging (1999) 0.98
Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. Hematology Am Soc Hematol Educ Program (2000) 0.95
Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients. Clin Pharmacol Ther (1998) 0.90
Oral anticoagulants. Pharmacologic issues for use in the elderly. Clin Geriatr Med (2001) 0.88
Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. Thromb Haemost (2003) 0.85
[Good management practices for oral anticoagulant overdose, situations of hemorrhagic risk and hemorrhagic events in patients taking oral anticoagulants in the ambulatory and hospital setting--April 2008]. J Mal Vasc (2008) 0.84
Genetic and environmental risk factors for oral anticoagulant overdose. Eur J Clin Pharmacol (2003) 0.83
[Prospective study of oral anticoagulation control in 110 very elderly hospitalized patients and of risk factors for poor control]. Presse Med (2008) 0.83
Large scale analysis of routine dose adjustments of mycophenolate mofetil based on global exposure in renal transplant patients. Ther Drug Monit (2011) 0.83
Pharmacokinetic considerations for digoxin in older people. Open Cardiovasc Med J (2011) 0.83
A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy. Clin Pharmacokinet (2012) 0.83
[Excess antivitamin K in elderly hospitalised patients aged over 70. A one-year prospective survey]. Presse Med (2003) 0.79
Prediction of fluindione maintenance dosage hampered by large intraindividual variability. Ther Drug Monit (2000) 0.77
Heparin bridging therapy and bleeding events in octogenarian inpatients with atrial fibrillation starting anticoagulation: results of an ancillary study. J Am Geriatr Soc (2011) 0.77
Modeling INR data to predict maintenance fluindione dosage. Ther Drug Monit (1998) 0.77
Management of oral anticoagulant in clinical practice: a retrospective study of 187 patients. J Gerontol A Biol Sci Med Sci (2004) 0.77
Beraprost sodium-fluindione combination in healthy subjects: pharmacokinetic and pharmacodynamic aspects. Fundam Clin Pharmacol (2004) 0.76
Rapid and simple micromethod for the quantification of fluindione in human plasma using high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl (1998) 0.76
[Anticoagulant clinic: a tool for reducing bleeding complications of oral anticoagulant treatment]. Rev Med Interne (2003) 0.76
Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology (2007) 2.61
Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004. Euro Surveill (2005) 2.20
Spurious counts and spurious results on haematology analysers: a review. Part II: white blood cells, red blood cells, haemoglobin, red cell indices and reticulocytes. Int J Lab Hematol (2007) 2.16
Use of Sysmex XE-2100 and XE-5000 hematology analyzers for the diagnosis of malaria in a nonendemic country (France). Int J Lab Hematol (2013) 1.99
Stops walking when talking: a predictor of falls in older adults? Eur J Neurol (2009) 1.96
Spurious counts and spurious results on haematology analysers: a review. Part I: platelets. Int J Lab Hematol (2007) 1.92
Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. J Infect Dis (2000) 1.86
Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. Hum Mol Genet (1994) 1.85
Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction. Clin Pharmacol Ther (2011) 1.67
Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs. Comput Methods Programs Biomed (2001) 1.57
Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci U S A (2000) 1.51
Key priorities in managing glucose control in older people with diabetes. J Nutr Health Aging (2009) 1.45
Silent T2* cerebral microbleeds: a potential new imaging clue in infective endocarditis. Neurology (2007) 1.45
Central auditory processing in aging: the dichotic listening paradigm. J Nutr Health Aging (2010) 1.44
Vitamin D-related changes in physical performance: a systematic review. J Nutr Health Aging (2009) 1.41
[Cholinesterase inhibitor therapy in long term care settings]. Rev Med Interne (2006) 1.39
Medication misuse in hospitalized patients with renal impairment. Int J Qual Health Care (2003) 1.38
Role of modelling and simulation in Phase I drug development. Eur J Pharm Sci (2001) 1.33
Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the nonparametric maximum likelihood method. J Pharmacokinet Biopharm (1998) 1.33
Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol (2000) 1.30
Emergency hospitalization in the elderly in a French university hospital: medical and social conditions and crisis factors precipitating admissions and outcome at discharge. Aging (Milano) (2001) 1.28
IANA (International Academy on Nutrition and Aging) Expert Group: weight loss and Alzheimer's disease. J Nutr Health Aging (2007) 1.28
Influence of the previous deep inspiration on the spirometric measurement of provoked bronchoconstriction in asthma. Am Rev Respir Dis (1981) 1.21
Use of corticosteroids in glomerulonephritis related to infective endocarditis: three cases and review. Clin Infect Dis (1999) 1.21
Effect of yohimbine on blood pressure in patients with depression and orthostatic hypotension induced by clomipramine. Clin Pharmacol Ther (1989) 1.21
Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features. Clin Microbiol Infect (2011) 1.18
Vitamin K epoxide reductase genetic polymorphism is associated with venous thromboembolism: results from the EDITH Study. J Thromb Haemost (2007) 1.16
A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther (1998) 1.13
Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir. Antimicrob Agents Chemother (2000) 1.12
Confirmation of the epsilon 4 allele of the apolipoprotein E gene as a risk factor for late-onset Alzheimer's disease. Neurology (1994) 1.12
Determination of twelve antiretroviral agents in human plasma sample using reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl (2000) 1.09
Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package. Anticancer Res (1995) 1.08
Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients. Clin Pharmacol Ther (2012) 1.08
How to manage recurrent falls in clinical practice: guidelines of the French Society of Geriatrics and Gerontology. J Nutr Health Aging (2011) 1.06
Serum dehydroepiandrosterone sulfate levels as an individual marker. J Clin Endocrinol Metab (1994) 1.05
Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther (2001) 1.05
Optimal design of a population pharmacodynamic experiment for ivabradine. Pharm Res (2001) 1.05
Changes in activity of vagal bronchopulmonary C fibres by chemical and physical stimuli in the cat. J Physiol (1981) 1.03
Association between nasal carriage of Staphylococcus aureus and infection in liver transplant recipients. Clin Infect Dis (2000) 1.02
Measurement of ornidazole by high-performance liquid chromatography. J Chromatogr (1983) 1.02
Phrenic afferents and their role in inspiratory control. J Appl Physiol (1985) (1986) 1.01
Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol (2004) 1.00
The pharmacokinetics and electrocardiographic effects of chloroquine in healthy subjects. Trop Med Parasitol (1994) 0.99
Perception of airway tone by asthmatic patients. Bull Eur Physiopathol Respir (1982) 0.99
Salivary cytomegalovirus (CMV) shedding, glycoprotein B genotype distribution, and CMV disease in human immunodeficiency virus-seropositive patients. Clin Infect Dis (2001) 0.99
Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey. Br J Clin Pharmacol (2007) 0.98
Prophylaxis of infective endocarditis: French recommendations 2002. Heart (2005) 0.98
Prevalence of sarcopenia in the French senior population. J Nutr Health Aging (2008) 0.98
Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity. Eur J Clin Pharmacol (1993) 0.98
Simultaneous determination of quinapril and its active metabolite quinaprilat in human plasma using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 0.97
High lipophilicity decreases drug transport across intestinal epithelial cells. J Pharmacol Exp Ther (1994) 0.97
Evaluation of tests based on individual versus population modeling to compare dissolution curves. J Biopharm Stat (2001) 0.97
Influence of gender and body composition on hydration and body water spaces. Clin Nutr (2008) 0.97
Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol (2001) 0.96
In-vitro resistance of Plasmodium falciparum to qinghaosu derivatives in west Africa. Lancet (1994) 0.96
Is there an association between serum 25-hydroxyvitamin D concentration and muscle strength among older women? Results from baseline assessment of the EPIDOS study. J Nutr Health Aging (2009) 0.95
Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial. Antimicrob Agents Chemother (2009) 0.95
Is low lower-limb kinematic variability always an index of stability? Gait Posture (2007) 0.95
Incidence and risk factors of bacterial pneumonia requiring hospitalization in HIV-infected patients started on a protease inhibitor-containing regimen. HIV Med (2006) 0.94
Infective endocarditis with symptomatic cerebral complications: contribution of cerebral magnetic resonance imaging. Cerebrovasc Dis (2013) 0.93
Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women. Clin Pharmacol Ther (2010) 0.93
Systemic polyarteritis nodosa diagnosed at hysterectomy. Am J Med (1987) 0.92
Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART. Br J Clin Pharmacol (2005) 0.92
Informed consent in clinical research in France: assessment and factors associated with therapeutic misconception. J Med Ethics (2008) 0.92
A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis (2007) 0.91
Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6--an evaluation with the nonparametric maximum likelihood method. Br J Clin Pharmacol (1994) 0.91
The aging process modifies the distensibility of elastic but not muscular arteries. Hypertension (1999) 0.91
[Plasma estimation of metronidazole by high performance liquid chromatography (author's transl)]. Ann Biol Clin (Paris) (1980) 0.91
Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients. Clin Pharmacol Ther (1998) 0.90
Impairment of muscle energy metabolism in patients with sleep apnoea syndrome. Respir Med (1997) 0.90
Caring the elderly diabetic patient with respect to concepts of successful aging and frailty. Diabetes Metab (2005) 0.90
Dehydroepiandrosterone replacement administration: pharmacokinetic and pharmacodynamic studies in healthy elderly subjects. J Clin Endocrinol Metab (2000) 0.90
Cross-resistance between mefloquine and halofantrine. Lancet (1990) 0.90
Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine. J Pharmacokinet Biopharm (1988) 0.89
[Iatrogenic central serous chorioretinopathy during glucocorticoid therapy for temporal arteritis]. Rev Med Interne (2006) 0.89
Pulmonary function changes 100 days and one year after bone marrow transplantation. Bone Marrow Transplant (1993) 0.89
Platelet inhibition by low-dose aspirin but not by clopidogrel reduces the axon-reflex current-induced vasodilation in humans. Am J Physiol Regul Integr Comp Physiol (2008) 0.89
Streptococcus bovis/Streptococcus equinus complex fecal carriage, colorectal carcinoma, and infective endocarditis: a new appraisal of a complex connection. Eur J Clin Microbiol Infect Dis (2013) 0.89
The effects of ischemia, lactic acid and hypertonic sodium chloride on phrenic afferent discharge during spontaneous diaphragmatic contraction. Neurosci Lett (1986) 0.88
Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients. HIV Med (2004) 0.88
A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients. Cancer Chemother Pharmacol (1991) 0.88
Peripheral antioxidant enzyme activities and selenium in elderly subjects and in dementia of Alzheimer's type--place of the extracellular glutathione peroxidase. Free Radic Biol Med (1996) 0.87
Comparison of lithium concentrations in red blood cells and plasma in samples collected for TDM, acute toxicity, or acute-on-chronic toxicity. Eur J Clin Pharmacol (2003) 0.87
Bayesian design criteria: computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model. J Pharmacokinet Biopharm (1995) 0.87
Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. Clin Pharmacol Ther (2007) 0.86
Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. Br J Clin Pharmacol (1997) 0.86
Treatment for tuberculosis-associated immune reconstitution inflammatory syndrome in 34 HIV-infected patients. Int J Tuberc Lung Dis (2012) 0.86
Stochastic optimization algorithms of a Bayesian design criterion for Bayesian parameter estimation of nonlinear regression models: application in pharmacokinetics. Math Biosci (1997) 0.86
The effects of electrical stimulation of myelinated and non-myelinated vagal motor fibres on airway tone in the rabbit and the cat. Respir Physiol (1988) 0.86
IAGG workshop: health promotion program on prevention of late onset dementia. J Nutr Health Aging (2011) 0.86
Mitochondrial function, energy expenditure, aging and insulin resistance. Diabetes Metab (2005) 0.85
Which breast cancer decisions remain non-compliant with guidelines despite the use of computerised decision support? Br J Cancer (2013) 0.85
Infective endocarditis prophylaxis: moving from dental prophylaxis to global prevention? Eur J Clin Microbiol Infect Dis (2012) 0.85
Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia. Eur J Clin Pharmacol (2014) 0.85
[Pharmacokinetics of prophylactic doses of chloroquine in 10 healthy volunteers. Preliminary results]. Bull Soc Pathol Exot Filiales (1985) 0.85
Amplification of AML1 gene is present in childhood acute lymphoblastic leukemia but not in adult, and is not associated with AML1 gene mutation. Leukemia (2002) 0.85
Vitamin D supplementation in older adults: searching for specific guidelines in nursing homes. J Nutr Health Aging (2013) 0.85